Prophylactic Strategies Improve Tolerability of Sacituzumab Govitecan in HER2-Negative Advanced Breast Cancer

During treatment with sacituzumab govitecan, neutropenia and diarrhea are common side effects and may lead to changes in the treatment. In this Medtalk, Antonio Llombart-Cussac from Hospital Arnau de Vilanova in Spain presents the results of the PRIMED study, published in The Lancet. PRIMED is the first published study to highlight preventive measures aimed at improving the tolerability of sacituzumab govitecan.